Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Dec:18:1534735418816825.
doi: 10.1177/1534735418816825. Epub 2018 Dec 3.

Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score-Matched Analysis

Sung Hwan Lee  1 , Ho Kyoung Hwang  1 , Chang Moo Kang  1 , Woo Jung Lee  1
Affiliations

Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score-Matched Analysis

Sung Hwan Lee et al. Integr Cancer Ther. 2019 Jan-Dec.

Abstract

Background: Surgical resection followed by adjuvant chemotherapy is the only therapeutic option in pancreatic cancer. However, there is limited research evaluating methods of improving adherence to adjuvant treatment after curative resection.

Methods: From January 1995 to December 2014, 323 patients with pancreatic cancer who underwent pancreatectomy at the Severance Hospital were enrolled in this study. We retrospectively analyzed clinicopathologic factors with propensity score matching method.

Results: The final study population was 217, after excluding patients undergoing neoadjuvant treatment or palliative resection, those who died within 30 days after operation, and those lost to follow-up after discharge. Among them, 161 received adjuvant treatment after curative resection. Cox's proportional hazard models revealed that nodal metastasis, perioperative transfusion, and completion of adjuvant treatment were significantly correlated with cancer recurrence and cancer-related death ( P < .05). Phellinus linteus (PL) medication was the only significant predictor for completion of adjuvant treatment after curative resection in logistic regression analysis ( P = .039). Disease-free and overall survival of the PL medication group were significantly higher than the no PL medication group ( P < .05).

Conclusions: PL medication potentially contributed to long-term oncologic outcomes by increasing patients' adherence to postoperative adjuvant chemotherapy, which resulted from PL medication associated with low toxicity of chemotherapy.

Keywords: adjuvant treatment; chemotherapy; pancreatic cancer; survival.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flow diagram of the study cohort of pancreatic ductal adenocarcinoma patients.
Figure 2.
Figure 2.
Survival analysis of the total population (n=217) and adjuvant treatment group (n = 161) after curative resection of pancreatic ductal adenocarcinoma.
Figure 3.
Figure 3.
Prescription details of Phellinus linteus (a, b, c), and effects of adjuvant treatment after curative resection of pancreatic ductal adenocarcinoma (PDAC) (d, e).
Figure 4.
Figure 4.
Survival analysis of propensity matched population on Phellinus linteus (PL) medication, with or without adjuvant treatment, after curative resection.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30. - PubMed
    1. Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12:1083-1093. - PubMed
    1. Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. doi: 10.1200/JCO.2016.67.5553 - DOI - PubMed
    1. Sohal DP, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34:2784-2796. doi: 10.1200/JCO.2016.67.1412 - DOI - PMC - PubMed
    1. Neoptolemos JP, Stocken DD, Friess H, et al. ; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210. - PubMed

Publication types

MeSH terms